Home » Posts tagged with » Breast Cancer
Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer. OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Its combination with the Pfizer breast cancer drug will be assessed in the […]

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]

Continue reading …
Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]

Continue reading …
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]

Continue reading …
Olema Oncology raises $54m for breast cancer drug candidate OP-1250

Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million in a Series B financing round, which was co-led by BVF Partners, Logos Capital, and Janus Henderson Investors. The US biopharma company will use the proceeds for advancing OP-1250, its lead drug candidate in breast cancer, into […]

Continue reading …
Genetron Health’s semiconductor-based NGS system gets Chinese approval

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the approval, the Chinese precision oncology company can launch the new desktop medium-throughput NGS system for clinical applications. The NGS system has been developed by Genetron Health for the detection of […]

Continue reading …
GE Healthcare unveils Serena Bright mammography solution for biopsy

GE Healthcare has unveiled new Serena Bright, a contrast-enhanced mammography solution for biopsy, which is claimed to help clinicians to detect breast cancer patients in a better way. The company claimed that SenoBright HD contrast-enhanced spectral mammography is an imaging tool for diagnosis that has the potential to detect malignant lesions which cannot be seen […]

Continue reading …
FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

Continue reading …
Puma secures FDA orphan drug status for NERLYNX in breast cancer with brain metastases

US biotech company Puma Biotechnology has secured orphan drug designation to NERLYNX (neratinib) from the US Food and Drug Administration (FDA) for the treatment of breast cancer patients having brain metastases, as per the latest pharma regulatory news. The FDA orphan drug designation program is given to investigational drugs designed for the treatment, prevention, or […]

Continue reading …
Imago Systems, Mayo Clinic to advance ICE Reveal for breast imaging

US medical imaging company Imago Systems and Mayo Clinic have signed a know-how license agreement to collaborate on breast imaging with the academic medical center to support clinical trial development and oversee the former’s reader studies for mammography. The multi-year agreement signed by the parties will focus on clinical trial support for the ICE Reveal […]

Continue reading …
Page 1 of 3123